Author

Hui-Jie Jia

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Attenuated Salmonella-Mediated Delivery of GSDMD Potentiates PD-1 Blockade Therapy against Melanoma

Immunotherapy has emerged as a core therapeutic strategy for melanoma. Programmed death protein 1 (PD-1) is a critical immune checkpoint molecule that restrains host anti-tumor immunity, and therapeutic agents blocking the PD-1 signaling pathway have been widely deployed in clinical practice. Nevertheless, single-agent...

Xiao-Long Jia, Ying-Jie Yuan, Yu-Jing Huang et al. · bioRxiv · 0 citations

Open access Oct 2026

Augmenting antitumor immunity in colon cancer via GSDMD-mediated pyroptosis induced by an attenuated Salmonella delivery system

As a major gastrointestinal malignancy, colon cancer (CC) demands more effective therapies. Gene therapy is an emerging promising strategy, and pyroptosis, a novel lytic cell death form, serves as a vital antitumor target, with Gasdermin D (GSDMD)—a key pore-forming protein in pyroptosis—showing anti-CC potential. We c...

Bing-Ran Han, X.-B. Si, Chuan-Jie Liu et al. · Immunologic research · 0 citations

Open access Aug 2026

Combination therapy with Nifuroxazide and Lenvatinib exerts superior anti-hepatocellular carcinoma effect by enhancing the anti-tumor immune response

Background Lenvatinib is a first-line multi-target tyrosine kinase inhibitor for hepatocellular carcinoma (HCC) that exerts anti-angiogenic effects by blocking VEGF signaling. However, its clinical efficacy is often compromised by adaptive resistance. Nifuroxazide, an anti-diarrheal agent, has been identified by our gr...

Jing Yang, Jia-Xin Geng, Yue-Ling Yin et al. · Frontiers in Oncology · 0 citations